Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2025 (2025-12-31): -15.89%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-12.83%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$10.59M
Return on Equity (ROE)
N/A
TTM Avg
216.74%
3Y Avg
-5384.23%
5Y Avg
-3626.91%
Market Cap
$10.59M
Return on Equity (ROE)
-310.94%
TTM Avg
727.99%
3Y Avg
459.17%
5Y Avg
300.20%
Market Cap
$10.52M
Return on Equity (ROE)
-252.37%
TTM Avg
-195.20%
3Y Avg
-116.68%
5Y Avg
-90.09%
Market Cap
$10.56M
Return on Equity (ROE)
-177.35%
TTM Avg
-89.62%
3Y Avg
-75.99%
5Y Avg
-59.80%
Market Cap
$10.84M
Return on Equity (ROE)
-477.54%
TTM Avg
-207.60%
3Y Avg
64.51%
5Y Avg
-22.91%
Market Cap
$10.51M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
Market Cap
$10.37M
Return on Equity (ROE)
-57.34%
TTM Avg
-65.47%
3Y Avg
-124.96%
5Y Avg
28.05%
Market Cap
$10.30M
Return on Equity (ROE)
N/A
TTM Avg
-652.54%
3Y Avg
-364.25%
5Y Avg
-252.47%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polyrizon Ltd. (PLRZ) | $10.83M | N/A | -12.83% | N/A | N/A |
| Pluri Inc. (PLUR)vs › | $10.59M | N/A | 216.74% | -5384.23% | -3626.91% |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.59M | -310.94% | 727.99% | 459.17% | 300.20% |
| Lifeward Ltd. (LFWD)vs › | $10.52M | -252.37% | -195.20% | -116.68% | -90.09% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.56M | -177.35% | -89.62% | -75.99% | -59.80% |
| Cerenome, Inc. (CNSY)vs › | $10.84M | -477.54% | -207.60% | 64.51% | -22.91% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A | -43.97% | -160.70% | -188.29% |
| Satellos Bioscience Inc. (MSLE)vs › | $10.37M | -57.34% | -65.47% | -124.96% | 28.05% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.30M | N/A | -652.54% | -364.25% | -252.47% |
| Valion Bio, Inc. (VBIO)vs › | $10.15M | -157.76% | -137.97% | -196.09% | -89.86% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -15.89% |
| 2025-09-30 | -5.40% |
| 2025-06-30 | -5.21% |
| 2025-03-31 | -8.41% |
| 2024-12-31 | -29.24% |
| 2024-09-30 | -18.88% |
